International Journal of Legal Medicine
March 1, 2016
Nicole Stachel, Andrea Jacobsen-Bauer, Gisela Skopp
Methoxydiphenidine (MXP) was first reported in 1989 as a dissociative anesthetic but did not enter the market for pharmaceuticals. The substance re-appeared in 2013 as a new psychoactive substance. A case of driving under the influence of MXP is reported. The concentration of MXP has been determined from a serum sample (57 ng/mL) by liquid chromatography tandem mass spectrometry following...
Psychopharmacology
September 27, 2011
Wendy M. Bosker, Kim P. C. Kuypers, Silke Conen et al.
32 citations
RATIONALE: Experimental research has shown that 3,4-methylenedioxymethamphetamine (MDMA) can improve some psychomotor driving skills when administered during the day. In real life, however, MDMA is taken during the night, and driving may likely occur early in the morning after a night of "raving" and sleep loss. OBJECTIVES: The present study assessed the effects of MDMA on road-tracking and...
European Addiction Research
2009
Derik Hermann, Tagrid Leménager, Jan Gelbke et al.
It is unclear whether impairment in decision making, measured by the Iowa Gambling Task (IGT), in addiction is substance-induced or the consequence of personality structure. Analysis of the IGT, the Tridimensional Personality Questionnaire (TPQ) and cannabinoids in hair and urine were performed in 13 cannabis users and matched controls. Hair Delta(9)-tetrahydrocannabinol (THC) correlated...
Biological Psychiatry
June 1, 2007
Derik Hermann, Alexander Sartorius, Helga Welzel et al.
Cannabinoids present neurotoxic and neuroprotective properties in in vitro studies, inconsistent alterations in human neuroimaging studies, neuropsychological deficits, and an increased risk for psychotic episodes. Proton magnetic resonance spectroscopy ((1)H-MRS), neuropsychological testing, and hair analysis for cannabinoids was performed in 13 male nontreatment-seeking recreational cannabis...